Figure A (Image 1)
Enoxaparin Sodium
Product Images NDC 50090-3445
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Enoxaparin Sodium (NDC 50090-3445). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure B (Image 2)
An instructional illustration showing a hand holding a prefilled syringe positioned near the lower abdomen, indicating the direction for subcutaneous injection. Another hand is stabilizing the injection site. The image demonstrates the proper technique for administering a subcutaneous injection.*
Figure C (Image 3)
An instructional illustration showing a hand holding a syringe with a thumb pressing on the plunger, indicating the action of injecting or expelling medication. An arrow points forward from the needle tip, suggesting the direction of injection.*
Figure D (Image 4)
An instructional black-and-white line drawing showing a hand holding a syringe with the thumb pressing on the plunger. An arrow points upward, indicating the plunger is to be pulled back or removed. The image likely demonstrates a step in preparing the syringe for injection.*
Figure E (Image 5)
An instructional illustration showing a gloved hand dropping a used syringe into a biohazard sharps disposal container labeled with the biohazard symbol and the word "BIOHAZARD" above the opening.*
Structural Formula (Image 6)
Chemical structure diagram of enoxaparin sodium, depicting the molecular framework with repeating units and variations in functional groups as indicated by R1 and R2 substituents.*
Structural Formula 2 (Image 7)
Chemical structure diagram of enoxaparin sodium, showing repeating disaccharide units with indicated chemical groups and variable components, including sodium carboxylate, hydroxyl groups, and sulfonated moieties, as well as ranges for variables X* and n representing structural variability.*
Figure 1 (Image 8)
A forest plot comparing relative risk between unfractionated heparin (UFH) and enoxaparin (Enox) across various patient subgroups for Enoxaparin Sodium by A-S Medication Solutions. The horizontal axis shows relative risk with a central line at 1, indicating no difference. Subgroups analyzed include sex, age, infarct location, diabetes status, prior myocardial infarction, fibrinolytic agent type, time to treatment, and PCI within 30 days. Each subgroup is represented by dots and confidence intervals showing which treatment may be better in terms of risk reduction.*
Figure 2 (Image 9)
A line chart comparing the hazard distribution function over time (days) to death or myocardial re-infarction for Enoxaparin and UFH (unfractionated heparin). The chart shows two lines representing each treatment, with Enoxaparin consistently lower than UFH. A smaller inset chart shows similar data over one year. The image includes risk numbers at various time points and statistical significance from log-rank tests.*
Label Image (Lbl500903445)
Label for Enoxaparin Sodium 40 mg/0.4 mL injection by A-S Medication Solutions. The label includes the NDC 50090-3445-0 and Product No. 6784-0. Instructions note storage at 68 to 77 degrees F and packaging as 10 x 0.4 mL single-dose syringes. Distributed by A-S Medication Solutions in Libertyville, Illinois.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
